Haploidentical Stem Cell Transplantation

The feasibility of stem cell transplantation across the major histocompatibility (MHC) barrier—as in haploidentical stem cell transplantation (SCT)—has been proved for some time in several studies. the main limitations include a higher graft failure rate, delayed immune reconstitution after transplantation with high rates of life-threatening infections, a higher incidence of post-transplant lymphoproliferative disease (PTLPD), and severe acute and chronic graft-versus-host disease (GVHD). In an attempt to reduce the transplant-related morbidity/mortality, several techniques had been evaluated involving conditioning regimen intensity, graft engineering, post-transplant cellular therapy and immunosuppression. this review will describe the current situation. it will also discuss initiatives and strategies to overcome the limitations associated with transplant across the MHC barrier.